Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor

Leukemia

Volumn 31, Issue 10, 2017, Pages 2151-2160

  Chen, K H ^a   Wada, M ^a   Pinz, K G ^a   Liu, H ^b   Lin, K W ^a   Jares, A ^b   Firor, A E ^a   Shuai, X ^c   Salman, H ^d   Golightly, M ^b   Lan, F ^d   Senzel, L ^b   Leung, E L ^e   Jiang, X ^a   Ma, Y ^a,b,e  

^a Long Island High Technology Incubator   (United States)

^b Stony Brook Medicine   (United States)

^c SICHUAN UNIVERSITY   (China)

^d STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^e MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CD137 ANTIGEN; CD137 LIGAND; CD28 ANTIGEN; CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN; CD8 ANTIGEN; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TNFRSF9 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; JURKAT CELL LINE; LYMPHOMA CELL LINE; MANTLE CELL LYMPHOMA CELL LINE; MOUSE; NK-92 CELL LINE; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; T CELL LEUKEMIA; T CELL LYMPHOBLASTIC LEUKEMIA CELL; T CELL LYMPHOMA; TUMOR CELL DESTRUCTION; TUMOR REGRESSION; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; COCULTURE; CYTOTOXICITY; DRUG SCREENING; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; LYMPHOMA, T-CELL, PERIPHERAL; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; PATHOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; SALVAGE THERAPY; TRANSPLANTATION; TUMOR CELL LINE;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD137; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD5; ANTIGENS, CD8; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL, PERIPHERAL; MICE; MOLECULAR TARGETED THERAPY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECOMBINANT FUSION PROTEINS; SALVAGE THERAPY; SINGLE-CHAIN ANTIBODIES; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019981328     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.8     Document Type: Article

References (33)

1. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011; 117: 6756-6767
2. Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood) 2015; 240: 1087-1098
3. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra138
4. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007; 13(18 Pt 1): 5426-5435
5. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10: 625-632
6. Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW, et al. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia 2016; 30: 701-707
7. Godfrey J, Benson DM Jr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma 2012; 53: 1666-1676
8. Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med 2016; 20: 1287-1294
9. Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014; 28: 917-927
10. Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget 2016; 7: 56219-56232
11. Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol 2015; 6: 21
12. Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy -advantages of the NK-92 cell line over blood NK cells. Front Immunol 2016; 7: 91
13. Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, et al. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother 2016; 65: 485-492
14. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 2013; 15: 1563-1570
15. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24: 1160-1170
16. Wu C, Hong SG, Winkler T, Spencer DM, Jares A, Ichwan B, et al. Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies. Mol Ther Methods Clin Dev 2014; 1: 14053
17. Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 2015; 23: 330-338
18. Zhang C, Burger MC, Jennewein L, Genssler S, Schonfeld K, Zeiner P, et al. ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J Natl Cancer Inst 2016; 108: djv375
19. Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 2009; 33: 1255-1259
20. Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, et al. Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2: e26527
21. Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol 2014; 8: 297-310
22. Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343-362
23. Campana D, van Dongen JJ, Mehta A, Coustan-Smith E, Wolvers-Tettero IL, Ganeshaguru K, et al. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood 1991; 77: 1546-1554
24. Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 plus rheumatoid arthritis investigators group. Arthritis Rheum 1993; 36: 620-630
25. Siena S, Bregni M, Formosa A, Brando B, Marenco P, Lappi DA, et al. Immunotoxinmediated inhibition of chronic lymphocytic leukemia cell proliferation in humans. Cancer Res 1989; 49: 3328-3332
26. Wacholtz MC, Lipsky PE. Treatment of lupus nephritis with CD5 PLUS, an immunoconjugate of an anti-CD5 monoclonal antibody and ricin A chain. Arthritis Rheum 1992; 35: 837-839
27. Fishwild DM, Strand V. Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function. J Rheumatol 1994; 21: 596-604
28. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267-276
29. Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 2015; 126: 983-992
30. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10: 535-544
31. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-2149
32. Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 2013; 24: 717-727
33. Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology 2014; 3: e28147